Xoma garners $30M in licensing pact

Xoma has produced fresh evidence of just how hot its technology is. Pfizer has licensed its tech for screening and manufacturing antibody products for $30 million upfront and a schedule of royalties and milestones. Berkeley, CA-based Xoma has already inked a string of licensing pacts with the likes of Merck, Centocor and Alexion and gets royalty checks from Lucentis, which was developed with its bacterial cell expression tech.

"This agreement provides clear validation of XOMA's antibody research," said Xoma CEO Steven Engle. Investors were clearly ready to see it his way, sending shares of Xoma up by 24 percent in early trading.

- see the release

Related Articles:
Engle named Xoma CEO, lands stock deal. Report
Biotech: An industry of the living dead? Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.